Payment overview · 2025
General Payments
$847.27
50 reported records · 16 companies
Healthcare provider profile · identity verified
Monte Edward Orahood, M.D,
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, TX · NPI 1114956414
Verified facts
What the public records show
CMS Open Payments records show Monte Edward Orahood, M.D, received $847.27 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.65 | 18.4% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.10 | 17.6% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.22 | 10.5% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $85.16 | 10.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $58.21 | 6.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.17 | 6.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.52 | 5.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $43.00 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.07 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.11 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.27 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.57 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.87 | 2.1% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.74 | 2.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.27 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $149.10 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $113.16 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $89.22 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $89.22 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $85.16 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $58.21 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.09 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 398 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
145 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
398 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 398 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 86 |
| Gabapentin | Gabapentin | 247 | 45 |
| Losartan Potassium | Losartan Potassium | 247 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 237 | 33 |
| Metformin Hcl | Metformin Hcl | 235 | 78 |
| Furosemide | Furosemide | 232 | 75 |
| Alprazolam | Alprazolam | 207 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 39 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 184 | 55 |
| Omeprazole | Omeprazole | 179 | 58 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 177 | 49 |
| Lisinopril | Lisinopril | 176 | 52 |
| Lorazepam | Lorazepam | 161 | 24 |
| Tramadol Hcl | Tramadol Hcl | 156 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 145 | 41 |
| Pregabalin | Pregabalin | 144 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 114 | 43 |
| Eliquis | Apixaban | 109 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 36 |
| Allopurinol | Allopurinol | 106 | 32 |
| Azithromycin | Azithromycin | 96 | 83 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 30 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 81 | 30 |
| Sertraline Hcl | Sertraline Hcl | 75 | 27 |
| Potassium Chloride | Potassium Chloride | 71 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 24 |
| Trazodone Hcl | Trazodone Hcl | 66 | 22 |
| Carvedilol | Carvedilol | 64 | 18 |
| Chlorthalidone | Chlorthalidone | 64 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 17 |
| Diazepam | Diazepam | 61 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 61 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 47 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 12 |
| Simvastatin | Simvastatin | 56 | 15 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Temazepam | Temazepam | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Entresto | Sacubitril/Valsartan | 50 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 15 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 49 | suppressed |
| Jardiance | Empagliflozin | 47 | 15 |
| Meloxicam | Meloxicam | 46 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 43 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 14 |
| Prednisone | Prednisone | 43 | 22 |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Levofloxacin | Levofloxacin | 39 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Famotidine | Famotidine | 37 | 11 |
| Finasteride | Finasteride | 37 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 18 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Cephalexin | Cephalexin | 25 | 24 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Clarithromycin | Clarithromycin | 17 | 15 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.27 · 50 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, AUSTEDO XR, Cologuard Collection Kit, FARXIGA, INSPIRE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TZIELD, Veozah, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error